Cargando…

Towards Optimized Bioavailability of (99m)Tc-Labeled Barbiturates for Non-invasive Imaging of Matrix Metalloproteinase Activity

INTRODUCTION: Dysregulated activity of matrix metalloproteinases (MMPs) drives a variety of pathophysiological conditions. Non-invasive imaging of MMP activity in vivo promises diagnostic and prognostic value. However, current targeting strategies by small molecules are typically limited with respec...

Descripción completa

Detalles Bibliográficos
Autores principales: Honold, Lisa, Austrup, Melanie, Faust, Andreas, Konken, Christian Paul, Schwegmann, Katrin, Zinnhardt, Bastian, Daniliuc, Constantin Gabriel, Haufe, Günter, Schäfers, Michael, Kopka, Klaus, Hermann, Sven
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9085681/
https://www.ncbi.nlm.nih.gov/pubmed/34750717
http://dx.doi.org/10.1007/s11307-021-01668-z
_version_ 1784703871649579008
author Honold, Lisa
Austrup, Melanie
Faust, Andreas
Konken, Christian Paul
Schwegmann, Katrin
Zinnhardt, Bastian
Daniliuc, Constantin Gabriel
Haufe, Günter
Schäfers, Michael
Kopka, Klaus
Hermann, Sven
author_facet Honold, Lisa
Austrup, Melanie
Faust, Andreas
Konken, Christian Paul
Schwegmann, Katrin
Zinnhardt, Bastian
Daniliuc, Constantin Gabriel
Haufe, Günter
Schäfers, Michael
Kopka, Klaus
Hermann, Sven
author_sort Honold, Lisa
collection PubMed
description INTRODUCTION: Dysregulated activity of matrix metalloproteinases (MMPs) drives a variety of pathophysiological conditions. Non-invasive imaging of MMP activity in vivo promises diagnostic and prognostic value. However, current targeting strategies by small molecules are typically limited with respect to the bioavailability of the labeled MMP binders in vivo. To this end, we here introduce and compare three chemical modifications of a recently developed barbiturate-based radiotracer with respect to bioavailability and potential to image MMP activity in vivo. METHODS: Barbiturate-based MMP inhibitors with an identical targeting unit but varying hydrophilicity were synthesized, labeled with technetium-99m, and evaluated in vitro and in vivo. Biodistribution and radiotracer elimination were determined in C57/BL6 mice by serial SPECT imaging. MMP activity was imaged in a MMP-positive subcutaneous xenograft model of human K1 papillary thyroid tumors. In vivo data were validated by scintillation counting, autoradiography, and MMP immunohistochemistry. RESULTS: We prepared three new (99m)Tc‐labeled MMP inhibitors, bearing either a glycine ([(99m)Tc]MEA39), lysine ([(99m)Tc]MEA61), or the ligand HYNIC with the ionic co-ligand TPPTS ([(99m)Tc]MEA223) yielding gradually increasing hydrophilicity. [(99m)Tc]MEA39 and [(99m)Tc]MEA61 were rapidly eliminated via hepatobiliary pathways. In contrast, [(99m)Tc]MEA223 showed delayed in vivo clearance and primary renal elimination. In a thyroid tumor xenograft model, only [(99m)Tc]MEA223 exhibited a high tumor-to-blood ratio that could easily be delineated in SPECT images. CONCLUSION: Introduction of HYNIC/TPPTS into the barbiturate lead structure ([(99m)Tc]MEA223) results in delayed renal elimination and allows non-invasive MMP imaging with high signal-to-noise ratios in a papillary thyroid tumor xenograft model. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s11307-021-01668-z.
format Online
Article
Text
id pubmed-9085681
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Springer International Publishing
record_format MEDLINE/PubMed
spelling pubmed-90856812022-05-11 Towards Optimized Bioavailability of (99m)Tc-Labeled Barbiturates for Non-invasive Imaging of Matrix Metalloproteinase Activity Honold, Lisa Austrup, Melanie Faust, Andreas Konken, Christian Paul Schwegmann, Katrin Zinnhardt, Bastian Daniliuc, Constantin Gabriel Haufe, Günter Schäfers, Michael Kopka, Klaus Hermann, Sven Mol Imaging Biol Research Article INTRODUCTION: Dysregulated activity of matrix metalloproteinases (MMPs) drives a variety of pathophysiological conditions. Non-invasive imaging of MMP activity in vivo promises diagnostic and prognostic value. However, current targeting strategies by small molecules are typically limited with respect to the bioavailability of the labeled MMP binders in vivo. To this end, we here introduce and compare three chemical modifications of a recently developed barbiturate-based radiotracer with respect to bioavailability and potential to image MMP activity in vivo. METHODS: Barbiturate-based MMP inhibitors with an identical targeting unit but varying hydrophilicity were synthesized, labeled with technetium-99m, and evaluated in vitro and in vivo. Biodistribution and radiotracer elimination were determined in C57/BL6 mice by serial SPECT imaging. MMP activity was imaged in a MMP-positive subcutaneous xenograft model of human K1 papillary thyroid tumors. In vivo data were validated by scintillation counting, autoradiography, and MMP immunohistochemistry. RESULTS: We prepared three new (99m)Tc‐labeled MMP inhibitors, bearing either a glycine ([(99m)Tc]MEA39), lysine ([(99m)Tc]MEA61), or the ligand HYNIC with the ionic co-ligand TPPTS ([(99m)Tc]MEA223) yielding gradually increasing hydrophilicity. [(99m)Tc]MEA39 and [(99m)Tc]MEA61 were rapidly eliminated via hepatobiliary pathways. In contrast, [(99m)Tc]MEA223 showed delayed in vivo clearance and primary renal elimination. In a thyroid tumor xenograft model, only [(99m)Tc]MEA223 exhibited a high tumor-to-blood ratio that could easily be delineated in SPECT images. CONCLUSION: Introduction of HYNIC/TPPTS into the barbiturate lead structure ([(99m)Tc]MEA223) results in delayed renal elimination and allows non-invasive MMP imaging with high signal-to-noise ratios in a papillary thyroid tumor xenograft model. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s11307-021-01668-z. Springer International Publishing 2021-11-08 2022 /pmc/articles/PMC9085681/ /pubmed/34750717 http://dx.doi.org/10.1007/s11307-021-01668-z Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Research Article
Honold, Lisa
Austrup, Melanie
Faust, Andreas
Konken, Christian Paul
Schwegmann, Katrin
Zinnhardt, Bastian
Daniliuc, Constantin Gabriel
Haufe, Günter
Schäfers, Michael
Kopka, Klaus
Hermann, Sven
Towards Optimized Bioavailability of (99m)Tc-Labeled Barbiturates for Non-invasive Imaging of Matrix Metalloproteinase Activity
title Towards Optimized Bioavailability of (99m)Tc-Labeled Barbiturates for Non-invasive Imaging of Matrix Metalloproteinase Activity
title_full Towards Optimized Bioavailability of (99m)Tc-Labeled Barbiturates for Non-invasive Imaging of Matrix Metalloproteinase Activity
title_fullStr Towards Optimized Bioavailability of (99m)Tc-Labeled Barbiturates for Non-invasive Imaging of Matrix Metalloproteinase Activity
title_full_unstemmed Towards Optimized Bioavailability of (99m)Tc-Labeled Barbiturates for Non-invasive Imaging of Matrix Metalloproteinase Activity
title_short Towards Optimized Bioavailability of (99m)Tc-Labeled Barbiturates for Non-invasive Imaging of Matrix Metalloproteinase Activity
title_sort towards optimized bioavailability of (99m)tc-labeled barbiturates for non-invasive imaging of matrix metalloproteinase activity
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9085681/
https://www.ncbi.nlm.nih.gov/pubmed/34750717
http://dx.doi.org/10.1007/s11307-021-01668-z
work_keys_str_mv AT honoldlisa towardsoptimizedbioavailabilityof99mtclabeledbarbituratesfornoninvasiveimagingofmatrixmetalloproteinaseactivity
AT austrupmelanie towardsoptimizedbioavailabilityof99mtclabeledbarbituratesfornoninvasiveimagingofmatrixmetalloproteinaseactivity
AT faustandreas towardsoptimizedbioavailabilityof99mtclabeledbarbituratesfornoninvasiveimagingofmatrixmetalloproteinaseactivity
AT konkenchristianpaul towardsoptimizedbioavailabilityof99mtclabeledbarbituratesfornoninvasiveimagingofmatrixmetalloproteinaseactivity
AT schwegmannkatrin towardsoptimizedbioavailabilityof99mtclabeledbarbituratesfornoninvasiveimagingofmatrixmetalloproteinaseactivity
AT zinnhardtbastian towardsoptimizedbioavailabilityof99mtclabeledbarbituratesfornoninvasiveimagingofmatrixmetalloproteinaseactivity
AT daniliucconstantingabriel towardsoptimizedbioavailabilityof99mtclabeledbarbituratesfornoninvasiveimagingofmatrixmetalloproteinaseactivity
AT haufegunter towardsoptimizedbioavailabilityof99mtclabeledbarbituratesfornoninvasiveimagingofmatrixmetalloproteinaseactivity
AT schafersmichael towardsoptimizedbioavailabilityof99mtclabeledbarbituratesfornoninvasiveimagingofmatrixmetalloproteinaseactivity
AT kopkaklaus towardsoptimizedbioavailabilityof99mtclabeledbarbituratesfornoninvasiveimagingofmatrixmetalloproteinaseactivity
AT hermannsven towardsoptimizedbioavailabilityof99mtclabeledbarbituratesfornoninvasiveimagingofmatrixmetalloproteinaseactivity